Program Announcement
for the
Department of Defense
Defense Health Program
Congressionally Directed Medical Research Programs

Ovarian Cancer Research Program
Clinical Development Award

Funding Opportunity Number: W81XWH-16-OCRP-CDA
Catalog of Federal Domestic Assistance Number: 12.420 Military Medical Research and Development

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), April 28, 2016
- Invitation to Submit an Application: June 2016
- Application Submission Deadline: 11:59 p.m. ET, August 10, 2016
- End of Application Verification Period: 5:00 p.m. ET, August 15, 2016
- Peer Review: October 2016
- Programmatic Review: December 2016

This Program Announcement/Funding Opportunity is one of two documents with instructions to prepare and submit an application for this funding opportunity. The second document, the General Application Instructions, is available for downloading from Grants.gov.
TABLE OF CONTENTS

I. Funding Opportunity Description .......................................................... 3  
   A. Program Description .................................................................. 3  
   B. Award Information ................................................................... 3  
   C. Eligibility Information ......................................................... 5  
   D. Funding .................................................................................. 5  
II. Submission Information ................................................................. 6  
   A. Where to Obtain the Grants.gov Application Package ............... 7  
   B. Pre-Application Submission Content ....................................... 7  
   C. Full Application Submission Content ..................................... 10  
   D. Applicant Verification of Grants.gov Submission in eBRAP ........ 16  
   E. Submission Dates and Times .................................................. 17  
   F. Other Submission Requirements ............................................. 17  
III. Application Review Information .................................................. 17  
   A. Application Review and Selection Process .............................. 17  
   B. Application Review Process .................................................. 18  
   C. Recipient Qualification ......................................................... 20  
   D. Application Review Dates ...................................................... 20  
   E. Notification of Application Review Results ............................ 20  
IV. Administrative Actions ................................................................. 20  
   A. Rejection .............................................................................. 20  
   B. Modification ......................................................................... 20  
   C. Withdrawal ........................................................................... 21  
   D. Withhold .............................................................................. 21  
V. Award Administration Information ............................................. 21  
   A. Award Notice ......................................................................... 21  
   B. Administrative Requirements .............................................. 22  
   C. National Policy Requirements .............................................. 22  
   D. Reporting .............................................................................. 22  
   E. Award Transfers ..................................................................... 22  
VI. Version Codes and Agency Contacts ......................................... 23  
   A. Program Announcement/Funding Opportunity and General Application Instructions Version .............................................. 23  
   B. CDMRP Help Desk ................................................................ 23  
   C. Grants.gov Contact Center ................................................... 23  
VII. Application Submission Checklist ............................................... 24
I.  **FUNDING OPPORTUNITY DESCRIPTION**

A.  **Program Description**

Applications to the Fiscal Year 2016 (FY16) Ovarian Cancer Research Program (OCRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs (OASD[HA]), the DHA RDA Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP).

The OCRP was initiated in FY97 to provide support for research of exceptional scientific merit. Appropriations for the OCRP from FY97 through FY15 totaled $256.45 million (M). The FY16 appropriation is $20M. For additional information concerning the OCRP and its current initiatives, long-term priorities and Programmatic Panel members, please refer to the OCRP website at [http://cdmrp.army.mil/ocrp/default](http://cdmrp.army.mil/ocrp/default).

The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer. Although not required, investigators are encouraged to address one of the FY16 Areas of Encouragement in their applications:

- Treatment resistance
- Optimizing immunotherapies
- Etiology, epidemiology and prevention
- Early detection including rare subtypes
- Understand host-tumor interactions
- Assessing early physiological changes of the tumor and the microenvironment in response to therapy

B.  **Award Information**

The OCRP Clinical Development Award is intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

The goal of this award mechanism is to accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. **Near-term clinical impact is expected.** Proof-of-concept demonstrating the potential utility of the proposed product or a prototype/preliminary version of the proposed product should already be established; thus, preclinical studies in animals are not allowed. Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed. Relevant data, either published or unpublished, that support the study rationale are required.
Important aspects of the application to the FY16 OCRP Clinical Development Award:

- The application should demonstrate availability of, and accessibility to, a suitable human subject population or anatomical samples that will support a meaningful outcome for the study. Include a discussion of feasibility of the proposal and how accrual goals will be achieved.

- The application should demonstrate documented availability of, and accessibility to, the drug/compound, device, and/or materials needed.

- The proposed study should include clearly defined and appropriate endpoints.

- The application should include a detailed statistical analysis plan, including a power analysis reflecting sample size projections that will clearly answer the objectives of the study.

- Applications must also include a transition plan (including potential funding and resources) showing how the result will progress to the next level of development (e.g., future clinical trials, delivery to the military or civilian market) after the completion of the OCRP award.

A clinical trial is defined as a prospective accrual of patients in which an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction.

Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All Department of Defense (DoD)-funded research involving new and ongoing research with human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO) prior to research implementation. This administrative review requirement is in addition to the local Institutional Review Board (IRB) or Ethics Committee (EC) review. Local IRB/EC approval at the time of submission is not required. The HRPO is mandated to comply with specific laws and requirements governing all research involving human anatomical substances, human subjects, or human cadavers that is supported by the DoD. These laws and requirements will necessitate information in addition to that supplied to the IRB/EC. Allow a minimum of 2 to 3 months for HRPO regulatory review and approval processes. Refer to the General Application Instructions, Appendix 6, and the Human Subject Resource Document available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) for additional information.

The CDMRP intends that information, data, and research resources generated under awards funded by this Program Announcement/Funding Opportunity be made available to the research community (which includes both scientific and consumer advocacy communities) and to the public at large. For additional guidance, refer to the General Application Instructions, Appendix 4, Section K.
C. Eligibility Information

- Independent investigator at or above the level of Assistant Professor (or equivalent) are eligible to submit applications.
- Cost sharing/matching is not an eligibility requirement.
- Eligible investigators must apply through an organization. Organizations eligible to apply include Federal agencies, national, international, for-profit, nonprofit, public, and private organizations.
- Applications with intramural (DoD) investigators named as the PI may be submitted as an “Extramural Submission” through an extramural (non-DoD) organization (e.g., non-profit foundation). An intramural investigator is defined as a DoD military or civilian employee working within a DoD laboratory or medical treatment facility, or working in a DoD activity embedded within a civilian medical center. Submissions from intramural (DoD) organizations are allowed and encouraged for this Program Announcement/Funding Opportunity. Applicants submitting through their intramural organizations are reminded to coordinate receipt and commitment of funds through their respective resource managers. *If an investigator at an intramural organization is named as a collaborator on an application submitted through an extramural organization, the application must include a letter from the collaborator’s Commander or Commanding Officer at the intramural organization that authorizes the collaborator’s involvement. Refer to the General Application Instructions, Appendix 1, for general eligibility information.*

D. Funding

- The maximum period of performance is 3 years.
- The anticipated direct costs budgeted for the entire period of performance will not exceed $600,000. Indirect costs are to be budgeted in accordance with the organization’s negotiated rate. No budget will be approved by the Government exceeding $600,000 direct costs or using an indirect rate exceeding the organization’s negotiated rate.
- All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.
- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

For this award mechanism, direct costs may be requested for (not at all-inclusive):

- Salary
- Research supplies
- Equipment
- Research-related subject costs
- Clinical trial costs
• Support for multidisciplinary collaborations, including travel
• Travel costs for one investigator to travel to one scientific/technical meeting per year
Shall not be requested for:
• Tuition

Awards to extramural organizations will consist solely of assistance agreements (Cooperative Agreements and Grants). Awards to intramural (DoD) agencies and other Federal agencies may be managed through a direct fund transfer (e.g., the Military Interdepartmental Purchase Request [MIPR] or Funding Authorization Document [FAD] process). Direct transfer of funds from the recipient to a DoD agency is not allowed except under very limited circumstances. Refer to the General Application Instructions, Section II.C.4., for budget regulations and instructions for the Research & Related Budget. For Federal agencies or organizations collaborating with Federal agencies, budget restrictions apply as are noted in Section II.C.4. of the General Application Instructions.

The CDMRP expects to allot approximately $2.88M of the $20M FY16 OCRP appropriation to fund approximately 3 Clinical Development Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program.

II. SUBMISSION INFORMATION

Submission of applications that are essentially identical or propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

Submission is a two-step process requiring both (1) pre-application submission through the electronic Biomedical Research Application Portal (eBRAP) (https://eBRAP.org/) and (2) application submission through Grants.gov (http://www.grants.gov/). Refer to the General Application Instructions, Section II.A., for registration and submission requirements for eBRAP and Grants.gov.

The pre-application and application submission process should be started early to avoid missing deadlines. There are no grace periods. Federal applicants must be familiar with Grants.gov requirements, including the need for an active System for Award Management (SAM) registration and a Data Universal Numbering System (DUNS) number. Refer to Appendix 3 of the General Application Instructions for further information regarding Grants.gov requirements.

eBRAP is a multifunctional web-based system that allows PIs to submit their pre-applications electronically through a secure connection, to view and edit the content of their pre-applications and full applications, to receive communications from the CDMRP, and to submit documentation during award negotiations and period of performance. A key feature of eBRAP is the ability of an organization’s representatives and PIs to view and modify the Grants.gov application submissions associated with them. eBRAP will validate Grants.gov application files against the specific Program Announcement/Funding Opportunity requirements and discrepancies will be
noted in an email to the PI and in the Full Application Files tab in eBRAP. It is the applicant’s responsibility to review all application components for accuracy as well as ensure proper ordering as specified in this Program Announcement/Funding Opportunity.

The application title, eBRAP log number, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent for the entire pre-application and application submission process. Inconsistencies may delay application processing and limit the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507 prior to the application deadline.

Application viewing, modification, and verification in eBRAP is strongly recommended, but not required. The Project Narrative and Budget cannot be changed after the application submission deadline. Prior to the full application deadline, a corrected or modified full application package may be submitted. Other application components may be changed until the end of the application verification period. After the end of the application verification period, the full application cannot be modified.

A. Where to Obtain the Grants.gov Application Package

To obtain the Grants.gov application package, including all required forms, perform a basic search using the Funding Opportunity Number W81XWH-16-OCR-P-CDA in Grants.gov (http://www.grants.gov).

B. Pre-Application Submission Content

The pre-application process should be started early to avoid missing deadlines. There are no grace periods. During the pre-application process, each submission is assigned a unique log number by eBRAP. This unique eBRAP log number should be included in the Grants.gov application and in all correspondence regarding the submission.

All pre-application components must be submitted by the PI through eBRAP (https://eBRAP.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the pre-application should be the same as those intended for the subsequent application submission. If any changes are necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.

The pre-application consists of the following components, which are organized in eBRAP by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):

- **Tab 1 – Application Information**

DoD FY16 OCRP Clinical Development Award 7
• Tab 2 – Application Contacts
  ○ Enter contact information for the PI. Enter the organization’s Business Official responsible for sponsored program administration (the “person to be contacted on matters involving this application” in Block 5 of the Grants.gov SF424 (R&R) Form). The Business Official must either be selected from the eBRAP list or invited in order for the pre-application to be submitted.
  ○ Select the performing organization (site at which the PI will perform the proposed work) and the contracting organization (organization submitting on behalf of the PI, which corresponds to Block 5 on the Grants.gov SF424 (R&R) Form), and click on “Add Organizations to this Pre-application.” The organization(s) must either be selected from the eBRAP drop-down list or invited in order for the pre-application to be submitted.
  ○ It is recommended that PIs identify an Alternate Submitter in the event that assistance with pre-application submission is needed.

• Tab 3 – Collaborators and Key Personnel
  ○ Enter the name, organization, and role of all collaborators and key personnel associated with the application.
  ○ FY16 OCRP Programmatic Panel members should not be involved in any pre-application or application. For questions related to Panel members and pre-applications or applications, refer to Section IV.C., Withdrawal, or contact the CDMRP Help Desk at help@eBRAP.org or 301-682-5507.
  ○ To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in application preparation, research, or other duties for submitted applications. For FY16, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website (http://cdmrp.army.mil/about/2tierRevProcess). Applications that include names of personnel from either of these companies will be administratively withdrawn unless plans to manage Conflicts of Interest (COIs) are provided and deemed appropriate by the Government. Refer to the General Application Instructions, Appendix 1, for detailed information.

• Tab 4 – Conflicts of Interest (COIs)
  ○ List all individuals other than collaborators and key personnel who may have a COI in the review of the application (including those with whom the PI has a personal or professional relationship). Refer to Appendix 1, Section C, of the General Application Instructions for further information regarding COIs.

• Tab 5 – Pre-Application Files
  
  Note: Upload documents as individual PDF files unless otherwise noted. eBRAP will not allow a file to be uploaded if the number of pages exceeds the limit specified below.
Preproposal Narrative (three-page limit): The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

The Preproposal Narrative should include the following:

- **Background/Readiness:**
  - Present the ideas and reasoning behind the proposed research; include relevant literature citations and published or unpublished data that led to the development of the proposed clinical study or clinical trial. If proposing a clinical trial, clearly describe the intervention and its target and mechanism of action.
  - Briefly state the qualifications of the PI and key personnel to perform the described research project.
  - If a clinical trial is proposed, provide readiness and/or anticipated first patient in (FPI) date and a brief timeline for accrual and endpoints readout.

- **Hypothesis/Objective, Specific Aims, and Approach:**
  - Concisely state the project’s hypothesis/objective and specific aims, and describe the scientific approach.

- **Impact:**
  - Explain why the proposed research is critical to the field. Describe the near-term impact, and how the proposed research will impact the clinical management of ovarian cancer.

Pre-Application Supporting Documentation: The items to be included as supporting documentation for the pre-application must be uploaded as individual files, and are limited to:

- **Additional Information (one-page limit):** One page for additional information can be used, at the PI’s discretion, to provide supporting data or rationale or justification for the pre-application. If no additional information will be submitted, include a page with the statement “No additional information.”

- **References Cited (one-page limit):** List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols used in the Preproposal Narrative.

- **PI Biographical Sketch (five-page limit):** Include a biographical sketch for the PI only.
• **Tab 6 – Submit Pre-Application**
  ○ This tab must be completed for the pre-application to be accepted and processed.

**Pre-Application Screening**

• **Pre-Application Screening Criteria**
  To determine the technical merits of the pre-application and the relevance to the mission of the DHP and the OCRP, pre-applications will be screened based on the following criteria:
  ○ **Intent of the Award Mechanism:** To what degree the proposed study has the potential to move promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.
  ○ **Hypothesis/Objective, Specific Aims, and Approach:** To what degree the experimental approach for accomplishing the specific aims is feasible and addresses the objectives.
  ○ **Impact:** How critical the proposed research is to ovarian cancer. To what extent the near-term impact of the proposed research, if successful, will affect the clinical management of ovarian cancer.

• **Notification of Pre-Application Screening Results**
  Following the pre-application screening, PIs will be notified as to whether or not they are invited to submit applications; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. The estimated timeframe for notification of invitation to submit an application is indicated on the title page of this Program Announcement/Funding Opportunity. Invitations to submit a full application are based on the Pre-Application Screening Criteria as published above.

**C. Full Application Submission Content**

The application process should be started early on Grants.gov to avoid missing deadlines. There are no grace periods. Verify the status of your organization’s Entity registration in the System for Award Management (SAM) well in advance of the application submission deadline. Allow 3 to 4 weeks to complete the entire SAM registration process. Refer to the General Application Instructions, Section II, for additional information.

*Applications will not be accepted unless the PI has received notification of invitation.*

*All contributors and administrators to the application must use matching compatible versions of Adobe software when editing and preparing application components. The use of different software versions will result in corruption of the submitted file. See Section II.C. of the General Application Instructions for details on compatible Adobe software.*

*The CDMRP cannot make allowances/exceptions to its policies for submission problems encountered by the applicant organization using system-to-system interfaces with Grants.gov.*
Each application submission must include the completed Grants.gov application package for this Program Announcement/Funding Opportunity. The Grants.gov application package is submitted by the Authorized Organizational Representative through the Grants.gov portal (http://www.grants.gov/).

Note: The Project Narrative and Budget Form cannot be changed after the application submission deadline.

If either the Project Narrative or the budget fails eBRAP validation or if the Project Narrative or Budget Form needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline.

Grants.gov application package components: For the Clinical Development Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. SF424 (R&R) Application for Federal Assistance Form: Refer to the General Application Instructions, Section II.C., for detailed information.

2. Attachments Form

Each attachment to the Grants.gov application forms must be uploaded as an individual PDF file in accordance with the formatting guidelines listed in Appendix 2 of the General Application Instructions. For all attachments, ensure that the file names are consistent with the guidance. Grants.gov will reject attachments with file names longer than 50 characters or incorrect file names that contain characters other than the following: A-Z, a-z, 0-9, underscore, hyphen, space, and period. In addition, Grants.gov has file size limits that may apply in some circumstances. Individual attachments may not exceed 20 MB and the file size for the entire Grants.gov application package may not exceed 200 MB.

- Attachment 1: Project Narrative (12-page limit): Upload as “ProjectNarrative.pdf.” The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings, etc.) used to describe the project. Inclusion of URLs that provide additional information to expand the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.
  - Background: Describe the ideas and reasoning on which the proposed work is based. Provide sufficient data, published or unpublished, to support the feasibility of work proposed. Demonstrate logical reasoning and provide a sound scientific rationale for the proposed project as established through a critical review and analysis of published literature. It is important to describe the studies showing proof of concept and clinical relevance.
  - Hypothesis/Objective: State the hypothesis to be tested or the objective to be reached.
- **Specific Aims:** Concisely explain the project’s specific aims to be funded by this award.

- **Research Strategy:** Provide a well-developed, well-integrated, and detailed research plan that supports the translational feasibility and promise of the approach. Describe the experimental design, methods, and analyses, including appropriate controls and endpoints in sufficient detail for analysis. Describe the availability of the necessary resources, including human subjects; include a detailed plan for the recruitment of subjects or acquisition of samples. Describe the statistical plan, including a power analysis reflecting sample size projections, that will address the hypothesis of the project. Explain how this research strategy will meet the proposed research goals. Describe potential challenges and alternative strategies where appropriate.

If a Clinical Trial is proposed, also include the following:

- If a small-scale clinical trial is proposed, the application must include documentation of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application or approval (i.e., file number of the application or the IND/IDE approval number). Describe the type of clinical trial to be performed (e.g., prospective, randomized, controlled) and outline the proposed methodology in sufficient detail to show a clear course of action.

- Identify the intervention to be tested and describe the projected outcomes.

- Define the study variables and describe how they will be measured. Include a description of appropriate controls and the endpoints to be tested.

- Describe the methods that will be used to recruit a sample of human subjects from the accessible population (e.g., convenience, simple random, stratified random). Provide information on the availability of, and access to, the appropriate patient population(s), as well as the ability to accrue sufficient subjects for the clinical trial. Provide readiness and/or anticipated first patient in (FPI) date and a brief timeline for accrual and endpoints readout.

- Describe the human subject-to-group assignment process (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group, or other procedures), if applicable. Explain the specific actions to accomplish the group assignment (e.g., computer assignment, use of table of random numbers).

- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested will result in the removal of those items or may result in administrative withdrawal of the application.
References Cited: List the references cited (including URLs, if available) in the Project Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms, and symbols.

Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether or not Government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present Government award under which the facilities or equipment items are now accountable. There is no form for this information.

Publications and/or Patents (five-document limit): Include relevant publication URLs and/or patents. If publications are not publicly available, then a copy/copies of the published manuscript(s) must be included in Attachment 2. Extra items will not be reviewed.

Letters of Organizational Support: Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, confirming the laboratory space, equipment, and other resources available for the project. Letters of support not requested in the Program Announcement/Funding Opportunity, such as those from members of Congress, do not impact application review or funding decisions.

Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.

Intellectual Property

- Background and Proprietary Information: All software and data first produced under the award are subject to a Federal purpose license. Therefore, it is important that you disclose/identify any Intellectual Property (software, data, patents, etc.) that will be used in performance of the project or provide a statement that none will be used. If applicable, state and identify the proprietary information that will be provided to the Government and indicate whether the applicant will require a waiver of the Federal purpose license. A term of the award requires the recipient to grant to the Government all necessary and appropriate licenses, which could include licenses to background and proprietary information that have been developed at private expense. Refer to the Code of Federal Regulations, Title 2, Part 200.315 (2 CFR 200.315).

- Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.
Data and Research Resources Sharing Plan: Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 4, Section K for more information about the CDMRP expectations for making data and research resources publicly available.

- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf.”** Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

The technical abstract is used by all reviewers. Of particular importance, programmatic reviewers typically do not have access to the full application and therefore rely on the technical abstract for appropriate description of the project’s key aspects. Therefore, clarity and completeness within the space limits of the technical abstract are highly important.

Technical abstracts should be written using the outline below:

- **Background:** Present the ideas and reasoning behind the proposed work.
- **Hypothesis/Objective:** State the hypothesis to be tested or the objective to be reached.
- **Provide evidence or rationale that supports the hypothesis/objective.**
- **Specific Aims:** State the specific aims of the study.
- **Study Design:** Describe the study design including appropriate controls.
- **Impact:** Describe how the proposed research is critical to the field. Describe the near-term clinical impact, and how the proposed research will impact the clinical management of ovarian cancer. Describe the potential impact of the proposed research on the health and welfare of military Service Members, their families, and other military beneficiaries.

- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf.”** The lay abstract is used by all reviewers. Abstracts of all funded research projects will be posted publicly. Do not include proprietary or confidential information. Use only characters available on a standard QWERTY keyboard. Spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

The lay abstract is an important component of the application review process because it addresses issues of particular interest to the consumer community. Do not duplicate the technical abstract. Lay abstracts should be written using the outline below:

- **Clearly describe, in a manner readily understood by lay persons, the rationale and objective for the proposed work.**
- **Describe the central problem addressed in the proposed research and how its resolution would impact the clinical management of ovarian cancer.**

DoD FY16 OCRP Clinical Development Award
Which individuals will it help, and how will it help them?
What are the potential clinical applications, benefits, and risks (potential near-term and long-term outcomes)?
What is the potential impact of the proposed research on the health and welfare of military Service members, their families, and other military beneficiaries?

- **Attachment 5: Statement of Work (SOW) (two-page limit):** Upload as “SOW.pdf.” The suggested SOW format and examples specific to different types of research projects are available on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm). For the Clinical Development Award mechanism, use the SOW format example titled “SOW (Statement of Work) Generic Format.” The SOW must be in PDF format prior to attaching. Refer to the General Application Instructions, Section II.C.2., for detailed guidance on creating the SOW.

- **Attachment 6: Impact Statement (one-page limit):** Upload as “Impact.pdf.” Explain why the proposed research is critical to the field, and how it will accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology. Describe the near-term clinical impact, and how the proposed research will impact the clinical management of ovarian cancer.

- **Attachment 7: Additional Information (one-page limit):** Upload as “AddInfo.pdf.” One page for additional information that the PI can use, at his/her discretion, to provide supporting data or rationale or justification for the proposed work. If no additional information will be supplied, leave Attachment 7 blank.

- **Attachment 8: Transition Plan (one-page limit):** Upload as “Transition.pdf.” Include a transition plan (including potential funding and resources) showing how the result will progress to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the OCRP award.

- **Attachment 9: Collaborating DoD Military Facility Budget Form(s), if applicable:** Upload as “MFBudget.pdf.” If a Military Facility (military health system facility, research laboratory, treatment facility, dental treatment facility, or a DoD activity embedded with a civilian medical center) will be a collaborator in performance of the project, complete the Collaborating DoD Military Facility Budget Form, available for download on the eBRAP “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm), including a budget justification, for each Military Facility as instructed. The costs per year should be included on the Grants.gov Research and Related Budget form under subaward costs. Refer to the General Application Instructions, Section II.C.7., for detailed information.
3. **Research & Related Senior/Key Person Profile (Expanded):** Refer to the General Application Instructions, Section II.C.4., for detailed information.

   - PI Biographical Sketch (five-page limit): Upload as “Biosketch_LastName.pdf.” The suggested biographical sketch format is available on the “Funding Opportunities & Forms” web page (https://ebrap.org/eBRAP/public/Program.htm) in eBRAP. The five-page National Institutes of Health Biographical Sketch may also be used. All biographical sketches should be submitted in the portable document format (pdf) that is not editable.
   
   Biographical Sketches should be used to demonstrate background and expertise through education, positions, publications, and previous work accomplished.

   - PI Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

   - Key Personnel Biographical Sketches (five-page limit each): Upload as “Biosketch_LastName.pdf.”

   - Key Personnel Previous/Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C.4., for detailed information.

   - Budget Justification (no page limit): Upload as “BudgetJustification.pdf.” The budget justification for the entire period of performance must be uploaded to the Research & Related Budget after completion of the budget for Period 1.

5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C.5., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C.6., for detailed information.

   Collaborating DoD Military Facilities Form: A Military Facility collaborating in the performance of the project should be treated as a subaward for budget purposes. However, do not complete the Grants.Gov R & R Subaward Budget Attachment Form; instead, complete the Collaborating DoD Military Facility Budget Form (use Attachment 9, Collaborating DoD Military Facility Budget Form) to show all direct and indirect costs. The costs per year should be included on the Grants.gov Research and Related Budget form under subaward costs. Refer to the General Application Instructions, Section II.C.7., for detailed information.

**D. Applicant Verification of Grants.gov Submission in eBRAP**

Prior to the end of the application verification period, PIs and organizational representatives can review and modify in eBRAP certain components of an application submitted to Grants.gov. Following retrieval and processing of the Grants.gov application, eBRAP will notify the organizational representatives and PI by email to log into eBRAP to review, modify, and verify the Grants.gov application submission. eBRAP will validate retrieved files against the specific
Program Announcement/Funding Opportunity requirements and discrepancies will be noted in both the email and in the Full Application Files tab in eBRAP. eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure proper ordering as specified in the Program Announcement/Funding Opportunity. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated Grants.gov application package must be submitted via Grants.gov as a “Changed/Corrected Application” with the previous Grants.gov Tracking ID prior to the application submission deadline. The Project Narrative and Budget Form cannot be changed after the application submission deadline.

E. Submission Dates and Times

All submission dates and times are indicated on the title page of this Program Announcement/Funding Opportunity. Pre-application and application submissions are required. Failure to meet either of these deadlines will result in submission rejection.

F. Other Submission Requirements

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines. All extramural applications must be submitted through Grants.gov. Applicant organizations and all subrecipient organizations must have a DUNS number to submit applications to Grants.gov. The applicant organization must also be registered in the Entity Management functional area of the SAM with an “Active” status to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Section II.A., for information on Grants.gov registration requirements.

III. APPLICATION REVIEW INFORMATION

A. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is peer review of applications against established criteria for determining technical merit. Each application is evaluated for its own merit, independent of other applications. The second tier is a programmatic review that makes recommendations for funding to the DHA RDA Directorate and the OASD(HA), based on technical merit, the relevance to the mission of the DHP and OCRP, the specific intent of the award mechanism, and to other specified evaluation criteria in the Program Announcement/Funding Opportunity. Programmatic review is a comparison-based process in which applications with scientific and technical merit compete in a common pool. The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in Section III.B.2, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Panel members sign a statement that application and evaluation information will not be disclosed outside the panel. Violations of confidentiality can result in the
dissolving of a panel(s) and other corrective actions. In addition, personnel at the applicant or collaborating organizations are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panel members or applicants that compromise the confidentiality of the review process may also result in suspension or debarment from Federal awards. Furthermore, the unauthorized disclosure of confidential information of one party to another third party is a crime in accordance with Title 18 United States Code 1905.

B. Application Review Process

1. Peer Review: To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:

   • **Research Strategy and Feasibility**
     - How well the scientific rationale supports the project and its feasibility as demonstrated by a critical review and analysis of published literature, logical reasoning, and presentation of published or unpublished data.
     - How well the hypothesis or objective, aims, experimental design, methods, statistical plan, and analyses are developed and integrated into the project.
     - To what extent the power analysis demonstrates that the sample size is appropriate to meet the objectives of the study. To what extent the data will be handled, collected, and analyzed in a manner that is consistent with the study aims.
     - How well the PI identifies potential problems and addresses alternative approaches.

   • **Clinical Strategy** (If a clinical trial is proposed)
     - How the type of clinical trial (e.g., prospective, randomized, controlled) proposed is appropriate to meet the project’s goals.
     - How the clinical trial is designed with appropriate study variables, controls, and endpoints with sufficient statistical power that will lead to meaningful results.
     - How the application demonstrates the availability of, and access to, the appropriate patient population(s). To what extent the application demonstrates readiness and achievable first patient in (FPI) date.

   • **Impact**
     - To what extent the proposed research is critical to ovarian cancer, and has near-term clinical impact including clinical management of ovarian cancer.
     - To what extent the proposed research will accelerate the clinical introduction of medical products and technologies that target ovarian cancer biology.
• **Personnel**
  - To what extent the PI and key personnel’s background and expertise will contribute to the success of the proposed project.
  - How the levels of effort are appropriate for successful conduct of the proposed work.

• **Transition Plan**
  - To what extent the strategies are feasible to transition to the next level of development (e.g., clinical trials, delivery to the military or civilian market) after the completion of the OCRP award.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

• **Environment**
  - How the research requirements are supported by the availability of and accessibility to facilities and resources (including collaborative arrangements, if applicable).
  - How the quality and extent of institutional support are appropriate for the proposed research.
  - If applicable, to what degree the intellectual and material property plan is appropriate.

• **Budget**
  - Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.

• **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influence the review.

2. **Programmatic Review:** To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

a. **Ratings and evaluations of the peer reviewers**

b. **Relevance to the mission of the DHP and FY16 OCRP, as evidenced by the following:**
   - Relative impact on ovarian cancer
   - Program portfolio composition
   - Adherence to the intent of the award mechanism
C.  **Recipient Qualification**

For general information on required qualifications for award recipients, refer to the General Application Instructions, Appendix 1.

D.  **Application Review Dates**

All application review dates and times are indicated on the [title page](#) of this Program Announcement/Funding Opportunity.

E.  **Notification of Application Review Results**

Each PI and organization will receive email notification of posting of the funding recommendation in eBRAP. Each PI will receive a peer review summary statement on the strengths and weaknesses of the application.

IV.  **ADMINISTRATIVE ACTIONS**

After receipt of pre-applications from eBRAP or applications from Grants.gov, the following administrative actions may occur:

A.  **Rejection**

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Submission of an application for which a letter of invitation was not received.
- Project Narrative is missing.
- Budget is missing.
- Project Narrative exceeds page limit.
- The PI does not meet the eligibility criteria
- Submission of the same research project to different Funding Opportunities within the same program and fiscal year.

B.  **Modification**

- Pages exceeding the specific limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.
C. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- An FY16 OCRP Programmatic Panel member is named as being involved in the research proposed or is found to have assisted in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation. *A list of the FY16 OCRP Programmatic Panel members can be found at [http://cdmrp.army.mil/ocrp/panels/panels16](http://cdmrp.army.mil/ocrp/panels/panels16).*
- The application fails to conform to this Program Announcement/Funding Opportunity description to the extent that appropriate review cannot be conducted.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- To preserve the integrity of its peer and programmatic review processes, the CDMRP discourages inclusion of any employee of its review contractors having any role in the preparation, research or other duties for submitted applications. For FY16, the identities of the peer review contractor and the programmatic review contractor may be found at the CDMRP website ([http://cdmrp.army.mil/about/2tierRevProcess](http://cdmrp.army.mil/about/2tierRevProcess)). Applications that include names of personnel from either of these companies will be administratively withdrawn unless plans to manage COIs are provided and deemed appropriate by the Government. Refer to the General Application Instructions, Appendix 1, for detailed information.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review process to gain protected evaluation information or to influence the evaluation process.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than September 30, 2017. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

Any assistance instrument awarded under this Program Announcement/Funding Opportunity will be governed by the award terms and conditions, which conform to DoD’s implementation of the Office of Management and Budget (OMB) circulars applicable to financial assistance. Terms and conditions of new awards made after December 26, 2014 may include revisions to reflect

B. Administrative Requirements

Refer to the General Application Instructions, Appendix 4 for general information regarding administrative requirements.

C. National Policy Requirements

Refer to the General Application Instructions, Appendix 5 for general information regarding national policy requirements.

D. Reporting

Refer to the General Application Instructions, Appendix 4, Section H, for general information on reporting requirements.

E. Award Transfers

Changes in PI are not allowed, except under extenuating circumstances that will be evaluated on a case-by-case basis and at the discretion of the Grants Officer. An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 4, Section L, for general information on organization or PI changes.
VI. VERSION CODES AND AGENCY CONTACTS

A. Program Announcement/Funding Opportunity and General Application Instructions Version

Questions related to this Program Announcement/Funding Opportunity should refer to the Program name, the Program Announcement/Funding Opportunity name, and the Program Announcement/Funding Opportunity version code [20160210c]. The Program Announcement/Funding Opportunity numeric version code will match the General Applications Instructions version code [20160210].

B. CDMRP Help Desk

Questions related to Program Announcement/Funding Opportunity content or submission requirements as well as questions related to the submission of the pre-application through eBRAP should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

  Phone: 301-682-5507
  Email: help@eBRAP.org

C. Grants.gov Contact Center

Questions related to application submission through Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

  Phone: 800-518-4726; International 1-606-545-5035
  Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity or by responding to the prompt provided by Grants.gov when first downloading the Grants.gov application package. If the Grants.gov application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
## VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Upload Order</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF424 (R&amp;R) Application for Federal Assistance</td>
<td></td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Attachments Form</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Project Narrative: Upload as Attachment 1 with file name “ProjectNarrative.pdf”</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Supporting Documentation: Upload as Attachment 2 with file name “Support.pdf”</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Technical Abstract: Upload as Attachment 3 with file name “TechAbs.pdf”</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Lay Abstract: Upload as Attachment 4 with file name “LayAbs.pdf”</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Statement of Work: Upload as Attachment 5 with file name “SOW.pdf”</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Impact Statement: Upload as Attachment 6 with file name “Impact.pdf”</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Additional Information: Upload as Attachment 7 with file name “AddInfo.pdf”</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Transition Plan: Upload as Attachment 8 with file name “Transition.pdf”</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Collaborating DoD Military Facility Budget Form(s): Upload as Attachment 9 with file name “MFBudget.pdf” if applicable.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research &amp; Related Senior/Key Person Profile (Expanded)</th>
<th>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Attach PI Previous/Current/Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Attach Previous/Current/Pending (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td>Complete as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research &amp; Related Budget</th>
<th>Complete as instructed.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R &amp; R Subaward Budget Attachment(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>